Cancer statistics: Current diagnosis and treatment of pancreatic cancer in Shanghai, China

被引:129
|
作者
Long, Jiang [1 ,2 ,3 ]
Luo, Guo-pei [1 ,2 ,3 ]
Xiao, Zhi-wen [1 ,2 ,3 ]
Liu, Zu-qiang [1 ,2 ,3 ]
Guo, Meng [1 ,2 ,3 ]
Liu, Liang [1 ,2 ,3 ]
Liu, Chen [1 ,2 ,3 ]
Xu, Jin [1 ,2 ,3 ]
Gao, Yu-tang [5 ]
Zheng, Ying [6 ]
Wu, Chunxiao [6 ]
Ni, Quan-xing [1 ,2 ,3 ]
Li, Min [1 ,2 ,3 ,4 ]
Yu, Xianjun [1 ,2 ,3 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat & Hepatobiliary Surg, Shanghai 200032, Peoples R China
[2] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200032, Peoples R China
[3] Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China
[4] Univ Texas Houston, Sch Med, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA
[5] Shanghai Canc Inst, Dept Epidemiol, Shanghai 200032, Peoples R China
[6] Shanghai Ctr Dis Control & Prevent, Dept Oncol, Shanghai 200336, PR, Peoples R China
基金
美国国家科学基金会;
关键词
Pancreatic cancer; Shanghai; Prognosis; Survival; DUCTAL ADENOCARCINOMA; CHEMOTHERAPY; EPIDEMIOLOGY; RESECTION; RISK; CHEMORADIOTHERAPY; SURVIVAL; TRENDS; CELLS; HEAD;
D O I
10.1016/j.canlet.2014.01.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A multi-center population-based study in Shanghai, China was performed to explore the implications for the management of pancreatic cancer by comparing diagnosis and survival rates. Novel imaging modalities including MRI (13.9%), PET/CT (1.8%), and EUS (5.6%) were not widely used in our population. Only 39.7% of cases were histologically verified (surgery with histologic diagnosis 31.0%, cytological diagnosis 8.7%, surgery without histologic diagnosis 12.1%, and clinical diagnosis 48.2%). Overall, 30.0% of patients underwent curative-intent operation, and only 9.8% of patients received comprehensive treatment. The prognosis of pancreatic cancer patients was significantly better for patients who were treated in high-volume centers than in low-volume centers. We propose that more effort should be put on novel diagnostic modalities, histological confirmation, and comprehensive treatment in China. Multidisciplinary teams specialized in pancreatic cancer therapy in high-volume centers are urgently needed. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:273 / 277
页数:5
相关论文
共 50 条
  • [21] Current therapies and advances in the treatment of pancreatic cancer
    Mancuso, Andrea
    Calabro, Fabio
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 58 (03) : 231 - 241
  • [22] Current views on surgical treatment of pancreatic cancer
    Obertop, H
    Pedrazzoli, S
    DIGESTIVE SURGERY, 1999, 16 (04) : 263 - 264
  • [23] Current Concepts in the Treatment of Resectable Pancreatic Cancer
    Marc T. Roth
    Jordan D. Berlin
    Current Oncology Reports, 2018, 20
  • [24] Pancreatic cancer: current management and treatment strategies
    Gall, Tamara M. H.
    Tsakok, Maria
    Wasan, Harpreet
    Jiao, Long R.
    POSTGRADUATE MEDICAL JOURNAL, 2015, 91 (1080) : 601 - 607
  • [25] Pancreatic cancer: Current and future treatment strategies
    Pliarchopoulou, K.
    Pectasides, D.
    CANCER TREATMENT REVIEWS, 2009, 35 (05) : 431 - 436
  • [26] Current status of pancreatic cancer treatment in Europe
    Macarulla, Teresa
    ANNALS OF ONCOLOGY, 2023, 34 : S1363 - S1363
  • [27] Current Treatment Strategies for Pancreatic Cancer in the Elderly
    Keiji Hanada
    Fumiaki Hino
    Hajime Amano
    Toshikatsu Fukuda
    Yoshinori Kuroda
    Drugs & Aging, 2006, 23 : 403 - 410
  • [28] Current Concepts in the Treatment of Resectable Pancreatic Cancer
    Roth, Marc T.
    Berlin, Jordan D.
    CURRENT ONCOLOGY REPORTS, 2018, 20 (05)
  • [29] Current and emerging therapies for the treatment of pancreatic cancer
    Moss, Rebecca A.
    Lee, Clifton
    ONCOTARGETS AND THERAPY, 2010, 3 : 111 - 127
  • [30] Current treatment strategies for pancreatic cancer in the elderly
    Hanada, Keiji
    Hino, Fumiaki
    Amano, Hajime
    Fukuda, Toshikatsu
    Kuroda, Yoshinori
    DRUGS & AGING, 2006, 23 (05) : 403 - 410